Bruker Co. (NASDAQ:BRKR) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 11.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 899,638 shares of the medical research company's stock after purchasing an additional 94,612 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.59% of Bruker worth $62,129,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tidal Investments LLC acquired a new stake in Bruker during the first quarter worth about $218,000. Virtu Financial LLC purchased a new stake in shares of Bruker during the 1st quarter valued at approximately $251,000. Atria Investments Inc acquired a new position in Bruker in the first quarter valued at approximately $1,142,000. Cetera Investment Advisers grew its position in Bruker by 350.0% in the first quarter. Cetera Investment Advisers now owns 33,131 shares of the medical research company's stock worth $3,112,000 after acquiring an additional 25,768 shares during the period. Finally, Cetera Advisors LLC acquired a new stake in Bruker during the first quarter worth $693,000. Institutional investors and hedge funds own 79.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Barclays decreased their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. Wells Fargo & Company lowered their price objective on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Citigroup cut their target price on Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. TD Cowen lowered their price target on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. Finally, Wolfe Research downgraded Bruker from an "outperform" rating to a "peer perform" rating in a report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $79.36.

Bruker Stock Down 0.7 %

Shares of Bruker stock traded down $0.43 on Friday, reaching $57.95. 805,902 shares of the company were exchanged, compared to its average volume of 1,114,335. The stock's 50 day moving average price is $60.63 and its 200-day moving average price is $64.09. The company has a market cap of $8.79 billion, a P/E ratio of 27.86, a price-to-earnings-growth ratio of 3.92 and a beta of 1.20. Bruker Co. has a 1-year low of $48.07 and a 1-year high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million during the quarter, compared to analysts' expectations of $866.46 million. During the same period in the previous year, the company posted $0.74 EPS. Bruker's quarterly revenue was up 16.4% compared to the same quarter last year. As a group, equities analysts forecast that Bruker Co. will post 2.4 EPS for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.35%. The ex-dividend date is Monday, December 2nd. Bruker's payout ratio is 9.62%.

Insider Buying and Selling at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the business's stock in a transaction on Monday, November 18th. The stock was bought at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares of the company's stock, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 28.30% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.